All In Biotech

Drug Trial Radar · NCT03520712

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

A Phase 1/2 Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL and Pre-existing Antibodies Against AAV5

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

3

Actual

Start

Apr 24, 2018

Primary completion

Aug 7, 2024

Study completion Aug 7, 2024

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
May 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, single dose study to determine the safety of valoctocogene roxaparvovec (an Adenovirus-Associated Virus (AAV) based gene therapy vector) in severe Hemophilia A patients with pre-existing antibodies against AAV5.

Conditions

  • Hemophilia A
  • Gene Therapy
  • Clotting Disorders
  • Blood Disorder

Interventions

  • Valoctocogene RoxaparvovecBiological

    Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse EventsTime frame: Up to 5 years post-infusion.

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center

    Johannesburg, South Africa

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

  • Royal Free Hospital

    London, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.